Dr Reddy's Laboratories has entered into a definitive agreement with Teva Pharmaceutical Industries Limited and an affiliate of Allergan plc to acquire a portfolio of eight Abbreviated New Drug Applications or ANDAs in the US for 350 million dollars in cash at closing. This acquired portfolio consists of products that are being divested by Teva as a precondition to its closing of the acquisition of Allergan's generics business. The acquisition of these A